Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
Adjuvant therapy recommendations for endometrial cancer were historically based on the individual patient’s risk of disease recurrence using clinicopathologic factors such as age, stage, histologic subtype, tumor grade, and lymphovascular space invasion. Despite the excellent prognosis for early sta...
Main Authors: | Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Giovanni Scambia, Domenica Lorusso |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.612450/full |
Similar Items
-
Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
by: Simona Duranti, et al.
Published: (2021-04-01) -
Immunotherapy in gynecological cancers
by: Domenica Lorusso, et al.
Published: (2021-02-01) -
PTEN and Gynecological Cancers
by: Camilla Nero, et al.
Published: (2019-09-01) -
Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01) -
Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
by: Camilla Nero, et al.
Published: (2021-03-01)